Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
1999-07-12
2008-03-11
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S178100, C424S185100, C424S192100, C424S193100, C514S012200, C530S324000
Reexamination Certificate
active
07341730
ABSTRACT:
This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating mammals with these anti-angiogenic polypeptides are provided, as well as the pharmaceutical compositions used to treat. Furthermore, the polypeptides of this invention can be used in fusion proteins, wherein the fusion proteins also comprise cell targeting or cytotoxic moieties. Also provided is the receptor to which these polypeptides bind.
REFERENCES:
patent: 5639876 (1997-06-01), Tripp et al.
patent: 5696080 (1997-12-01), O'Brien et al.
patent: 5716614 (1998-02-01), Katz et al.
patent: 5888474 (1999-03-01), Dean et al.
patent: 5910568 (1999-06-01), Hammerstedt et al.
patent: 6403782 (2002-06-01), Luster et al.
patent: 95/03821 (1995-02-01), None
patent: WO 97/25620 (1997-07-01), None
Stevens, R.L. et al. Biochemistry 32: 4051-4059, 1993.
Hakansson, A., et al. Experimental Cell Research, 246: 451-460, 1999.
Collard, Michael W. et al., “Biosynthesis and Moelcular Cloning of Sulfated Glycoprotein 1 Secreted by Rat Sertoli Cells: Seqeucne ;similarity with the 70 Kilodalton Precurson to Sulfatide/Gm1 Activator,” (1988) Biochemistry, 27; 4557-4564.
Genbank Accession No. AAA60303 Prosaposin.
Hiraiwa, Masao et al., “The Effect of Carbohydrate Removal on Stability and Activity of Saposin B” (1993) Arch. Biochem. Biophys. 202: 326.
Kase, Ryoichi et al. “Only sphingolipid activator protein B (SAP-B or saposin B) stimulates the degradation of globotriaosylceramide by recombinant human lysosomal alpha-galactosidase in a determgent-gree liposomal system,” (1996) FEBS Lett. 393: 74-76.
Kretz, Keith A. et al. “Characterization of a mutation in a family of saposin B deficiency: A glycosylation site defect,” (1990) Proc. Natl. Acad. Sci. USA, 87: 2541-2544.
Lamontagne, Sonia et al., “Modulation of Human Saposin B Sphingolipid-binding Specificity by Alternative Splicing,” (1994) J. Biol. Chem., 269: 20528-20532.
Zetter, Bruce R., “Angiogenesis And Tumor Metastasis,” (1998) Annu. Rev. Med. 49: 407-24.
Liepinsh, Edvards et al., “Saposin Fold Revealed By The NMR Structure Of NK-lysin,” (1997)Nature Structural Biology, vol. 4, No. 10, pp. 793-795.
Pointing, Christopher P. et al., “Swaposins: Circular Permutations Within Genes Encoding Saposin Homologues,” (1995)Trends In Biochemical Sciences, vol. 20, No. 5, pp. 179-180.
Sano, Akira, et al., “Sphingolipid Hydrolase Activator Proteins and Their Precursors,”Biochemical and Physical Research Communication, 165(3) (1989), pp. 1191-1197.
International Search Report from PCT US99/15772, mailed on Oct. 28, 1999.
Helms Larry R.
Hogan & Hartson LLP
Holleran Anne L.
University of Southern California
LandOfFree
Inhibitors of angiogenesis and tumor growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of angiogenesis and tumor growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of angiogenesis and tumor growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3977426